title: Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
abstract: We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis C had preceded the development of B-cell non-Hodgkin's lymphoma. The patient had previously failed numerous attempts to clear the hepatitis C virus with traditional antiviral schedules. We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy. This report also suggests that eradication of hepatitis C virus may result in the short-term prevention of B-cell non-Hodgkin's lymphoma relapse. The findings from our case require further validation in future cohorts of patients.
authors.affiliation: Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, Via Giardini 1355, Modena, Italy. Electronic address: dante.romagnoli@unimore.it.
authors.forename: Dante
authors.initials: D
authors.lastname: Romagnoli
authors.affiliation: Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, Via Giardini 1355, Modena, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Marrazzo
authors.affiliation: Division of Internal Medicine, Pavullo Hospital, Pavullo 41026, Modena, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Ballestri
authors.affiliation: Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, Via Giardini 1355, Modena, Italy.
authors.forename: Amedeo
authors.initials: A
authors.lastname: Lonardo
authors.affiliation: Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, Via Giardini 1355, Modena, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bertolotti
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000821:virology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: B-cell non-Hodgkin’s lymphoma; Difficult-to-treat; Direct-acting antiviral agent; Hepatitis C virus; Sofosbuvir